A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults

OBJECTIVE: To evaluate single zuranolone (SAGE‐217) 30 or 45 mg doses in a 5‐h phase advance insomnia model. METHODS: In this double‐blind, three‐way crossover study, healthy adults received placebo (n = 41), zuranolone 30 mg (n = 44), and zuranolone 45 mg (n = 42) across three treatment periods. Sl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bullock, Amy, Gunduz‐Bruce, Handan, Zammit, Gary K., Qin, Min, Li, Haihong, Sankoh, Abdul J., Silber, Christopher, Kanes, Stephen J., Jonas, Jeffrey, Doherty, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286466/
https://www.ncbi.nlm.nih.gov/pubmed/34352138
http://dx.doi.org/10.1002/hup.2806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9286466/
https://www.ncbi.nlm.nih.gov/pubmed/34352138
http://dx.doi.org/10.1002/hup.2806

Ejemplares similares